share_log

InspireMD (NYSE:NSPR) Receives New Coverage From Analysts at StockNews.com

Financial News Live ·  Sep 6, 2022 02:11

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR – Get Rating) in a report published on Friday. The brokerage issued a sell rating on the stock.

InspireMD Stock Down 1.2 %

NSPR stock opened at $1.70 on Friday. The stock's 50 day simple moving average is $1.92 and its 200 day simple moving average is $2.32. InspireMD has a fifty-two week low of $1.68 and a fifty-two week high of $5.06.

Get InspireMD alerts:

InspireMD (NYSE:NSPR – Get Rating) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.59) EPS for the quarter. The company had revenue of $1.53 million for the quarter. InspireMD had a negative return on equity of 54.85% and a negative net margin of 334.66%.

InspireMD Company Profile

(Get Rating)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.

Further Reading

  • Get a free copy of the StockNews.com research report on InspireMD (NSPR)
  • What Does an Inverted Yield Curve Mean For You?
  • SPY vs. QQQ: Which ETF Wins in 2022?
  • Could Snap Stock Rebound As Management Restructures?
  • MarketBeat: Week in Review 8/29 – 9/2
  • Hormel Looks Cheap At These Levels

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment